Tacrolimus (FK506) versus cyclosporin a microemulsion (neoral) maintenance immunosuppression: Effects on graft survival and function, infection, and metabolic profile following kidney transplantation (KT)

Molecular Immunology

Volumn 39, Issue 17-18, 2003, Pages 1095-1100

  Abou Jaoude, Maroun M ^a   Ghantous, Imad ^a   Almawi, Wassim Y ^b  

^a SAINT GEORGE HOSPITAL UNIVERSITY MEDICAL CENTER   (Lebanon)

^b ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

Cyclosporin; Kidney transplantation; Tacrolimus

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN; TACROLIMUS;

ADULT; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEMOGRAPHY; GRAFT INFECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MEDICAL ASSESSMENT; PRIORITY JOURNAL; RECIPIENT;

CUCUMBER MOSAIC VIRUS;

EID: 0038771219     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(03)00070-1     Document Type: Conference Paper

References (24)

1. Abouljoud M., Kumar M.S., Brayman K., Emre S., Bynon S.J. Conversion to neoral provides effective rescue therapy for liver and kidney transplant patients intolerant of Prograf. Transplant. Proc. 33:2001;1027-1028.
2. Almawi W.Y., Melemedjian O.K. Clinical and mechanistic differences between FK506 (tacrolimus) and cyclosporin A. Nephrol. Dial. Transplant. 15:2000;1916-1918.
3. Baan C.C., van Riemsdijk C., van Overbeeke I.C., Balk A.H., Vantrimpont P.M., Mol W.M., Knoop C.J., Niesters H.G., Maat L.P., Weimar W. Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-beta 1 type I receptor expression. Clin. Transplant. 15:2001;276-283.
4. Blume C., Hollenbeck M., Ivens K., Heering P., Hetzel G.R., Grabensee B. Conversion from cyclosporine to tacrolimus prevents transplant function loss due to acute steroid-resistant or chronic rejection in renal allograft recipients. Transplant. Proc. 33:2001;3161-3163.
5. Boots J.M., van Duijnhoven E.M., Christiaans M.H., Nieman F.H., van Suylen R.J., van Hooff J.P. Single-center experience with tacrolimus versus cyclosporine-neoral in renal transplant recipients. Transplant. Int. 14:2001;370-383.
6. Chand D.H., Southerland S.M., Cunningham R.J. III Tacrolimus: the good, the bad, and the ugly. Pediat. Transplant. 5:2001;32-36.
7. Graham R.M. Cyclosporine: mechanisms of action and toxicity. Cleve. Clin. J. Med. 61:1994;308-313.
8. Hadley S., Samore M.H., Lewis W.D., Jenkins R.L., Karchmer A.W., Hammer S.M. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation. 59:1995;851-859.
9. Hohage H., Bruckner D., Arlt M., Buchholz B., Zidek W., Spieker C. Influence of cyclosporine A and FK506 on 24 h blood pressure monitoring in kidney transplant recipients. Clin. Nephrol. 45:1996;342-344.
10. Israni A., Brozena S., Pankewycz O., Grossman R., Bloom R. Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients. Am. J. Kidney Dis. 39:2002;E16.
11. Jang H.J., Kim S.C., Han D.J. Conversion from cyclosporine to tacrolimus in renal allograft recipients with delayed graft function from severe acute tubular necrosis. Transplant. Proc. 32:2000;1714-1715.
12. Kohnle M., Zimmermann U., Lutkes P., Albrecht K.H., Philipp T., Heemann U. Conversion from cyclosporine A to tacrolimus after kidney transplantation due to hyperlipidemia. Transplant. Int. 13:2000;S345-S348.
13. Krentz A.J., Dmitrewski J., Mayer D., McMaster P., Buckels J., Dousset B., Cramb R., Smith J.M., Nattrass M. Post-operative glucose metabolism in liver transplant recipients. A 2-year prospective randomized study of cyclosporine versus FK506. Transplantation. 57:1994;1666-1669.
14. Mayer A.D., Dmitrewski J., Squifflet J.P., Besse T., Grabensee B., Klein B., Eigler F.W., Heemann U., Pichlmayr R., Behrend M.et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation. 64:1997;436-443.
15. Mazariegos G.V., Salzedas A.A., Jain A., Reyes J. Conversion from cyclosporin to tacrolimus in paediatric liver transplant recipients. Paediat. Drugs. 3:2001;661-672.
16. Pirsch J.D. Cytomegalovirus infection and post-transplant lymphoproliferative disease in renal transplant recipients: results of the US multicenter FK506 Kidney Transplant Study Group. Transplantation. 68:1999;1203-1205.
17. Pirsch J.D., Miller J., Deierhoi M.H., Vincenti F., Filo R.S. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation. 63:1997;977-983.
18. Reyes J., Jain A., Mazariegos G., Kashyap R., Green M., Iurlano K., Fung J. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. Transplantation. 69:2000;2573-2580.
19. Selzner N., Durand F., Bernuau J., Heneghan M.A., Tuttle-Newhall J.E., Belghiti J., Clavien P.A. Conversion from cyclosporine to FK506 in adult liver transplant recipients: a combined North American and European experience. Transplantation. 72:2001;1061-1065.
20. Schroeder T.J., Weiss M.A., Smith R.D., Stephens G.W., First M.R. The efficacy of OKT3 in vascular rejection. Transplantation. 51:1991;312-315.
21. Thorp M., DeMattos A., Bennett W., Barry J., Norman D. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. Transplantation. 69:2000;1218-1220.
22. Trompeter R., Filler G., Webb N.J., Watson A.R., Milford D.V., Tyden G., Grenda R., Janda J., Hughes D., Ehrich J.H., Klare B., Zacchello G., Bjorn Brekke I., McGraw M., Perner F., Ghio L., Balzar E., Friman S., Gusmano R., Stolpe J. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediat. Nephrol. 17:2002;141-149.
23. Verleden G.M., Besse T., Maes B. Successful conversion from cyclosporine to tacrolimus for gastric motor dysfunction in a lung transplant recipient. Transplantation. 73:2002;1974-1976.
24. Vincenti F., Jensik S.C., Filo R.S., Miller J., Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at 5 years. Transplantation. 15(73):2002;775-782.